Physician profile
Stephen E Weis
NPI 1396700399
$31,154.96
in general payments reported to CMS, 2019-2025
38 companies · $5,266 in 2025
The $5,266 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,983 · 2020: $2,419 · 2021: $4,080 · 2022: $5,720 · 2023: $5,072 · 2024: $4,615 · 2025: $5,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,754.33 |
| Education | $198.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,597.83 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $3,059.98 | 2019-2025 | |
| Janssen Biotech, INC. | $2,687.67 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $2,287.06 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $1,887.09 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,781.33 | 2020-2025 | Ilumya, Blu-U, Odomzo |
| Pfizer INC. | $1,492.78 | 2019-2025 | |
| Amgen INC. | $1,408.50 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $1,202.84 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $946.52 | 2022-2025 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $865.19 | 2021-2025 | Tremfya |
| Incyte Corporation | $737.99 | 2021-2025 | Opzelura, Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $694.72 | 2019-2025 | Arazlo, Siliq, Jublia |
| Galderma Laboratories, L.P. | $660.02 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Arcutis Biotherapeutics, INC. | $646.60 | 2023-2025 | Zoryve |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $613.44 | 2022-2024 | Vtama |
| Leo Pharma INC. | $462.23 | 2020-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.22 | 2022-2024 | Spevigo |
| Johnson & Johnson Health Care Systems INC. | $388.95 | 2022-2025 | Tremfya |
| Kyowa Kirin, INC. | $342.40 | 2022-2025 | Poteligeo |
| E.R. Squibb & Sons, L.L.C. | $322.46 | 2022-2025 | Sotyktu |
| Genentech USA, INC. | $288.61 | 2019-2022 | |
| Dusa Pharmaceuticals, INC. | $195.20 | 2019 | |
| Sandoz INC. | $181.58 | 2023-2024 | Hyrimoz |
| Almirall LLC | $162.23 | 2019-2025 | Klisyri |
| Springworks Therapeutics, INC. | $160.06 | 2025 | Gomekli |
| Fresenius Kabi USA, LLC | $148.86 | 2023-2024 | Idacio |
| Helsinn Therapeutics (U.S.), INC. | $103.88 | 2021 | |
| Organon LLC | $98.05 | 2025 | Vtama |
| Tactile Systems Technology INC | $77.94 | 2019-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Blueprint Medicines Corporation | $70.82 | 2025 | Ayvakit |
| Botanix Sb INC | $62.15 | 2025 | Sofdra |
| Novocure INC. | $37.50 | 2021 | |
| Vyne Pharmaceuticals INC. | $23.29 | 2020 | |
| Mimedx Group, INC. | $21.01 | 2024 | |
| Jazz Pharmaceuticals INC. | $18.95 | 2019 | |
| Exact Sciences Corporation | $15.95 | 2025 | Cologuard Collection Kit |
| Pierre Fabre Pharmaceuticals, INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Weis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.